RedHill Biopharma Ltd. (RDHL) stock prices were down by 5.40% as of the market closing on August 25th 2021. This brought the price per share down to USD$7.18 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 11.14%, bringing the price per share up to USD$7.98.
RDHL Stock’s Opaganib
August 26th, 2021 saw RDHL stock announce the preliminary results of a new preclinical study. The results showed opaganib as inhibiting Delta variant replication of Covid-19. The treatment does this while maintaining cell viability at relevant concentrations. The company is collaborating with the University of Louisville Center for Predictive Medicine to study opaganib. The treatment was studied in a 3D tissue model of human bronchial epithelial cells in an effort to evaluate the in vitro efficacy of the treatment in inhibiting the Delta variant of Covid-19. The Delta variant is the newest to have been found to be inhibited by opaganib, with the Alpha, Beta, and Gamma variants of Covid-19 having been previously demonstrated to be inhibited by the treatment.
Addressing Proliferation of Covid-19 Variants
The results are the latest in a growing plethora of evidence that support the possible essential role played by sphingosine kinase-2 in the replication of RNA viruses such as Covid-19. This activity is not contingent on the nature of the mutation of the spike protein being targeted. This makes inhibition of the intra-cellular enzyme a promising therapeutic target for treating the coronavirus pandemic.
RDHL Stock Tackles the Pandemic
RDHL stock has accumulated extensive evidence from its preclinical undertakings of opaganib’s potential ability to inhibit various variants of SARS-CoV-2. The treatment has been established to treat the emerging Delta variant and is expected to be applicable to newer variants if/as they emerge. The strong antiviral and anti-inflammatory activities of oral opaganib potentially address both the viral cause and inflammatory effects of Covid-19.
About Opaganib
Opaganib is a leading novel small molecule investigational oral pill in development for the treatment of Covid-19. It is a unique host targeted, dual antiviral, and anti inflammatory drug that acts on the cause and effect of the coronavirus. The treatment is believed to exert its antiviral effect by selectively inhibiting SK2, which is a key enzyme produced in human cells that may be recruited by the virus to facilitate its replication.
Future Outlook for RDHL Stock
The company reported a strong quarter, most recently consolidated by the success of the company’s development of opaganib. With the world hurtling towards universal immunizations, the company is poised to capitalize on the expanded scope of opportunities presented to it. Investors are hopeful that the company will be able to facilitate significant and sustained increases in shareholder value.
